Related Experiment Video
Updated: Jul 27, 2025
High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes
Sai Wang1, Haiman Hou1, Yao Tang1
1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Abstract:
Paraneoplastic neurological syndrome refers to certain malignant tumors that have affected the distant nervous system and caused corresponding dysfunction in the absence of tumor metastasis. Patients with this syndrome produce multiple antibodies, each targeting a different antigen and causing different symptoms and signs. The CV2/collapsin response mediator protein 5 (CRMP5) antibody is a major antibody of this type. It damages the nervous system, which often manifests as limbic encephalitis, chorea, ocular manifestation, cerebellar ataxia, myelopathy, and peripheral neuropathy. Detecting CV2/CRMP5 antibody is crucial for the clinical diagnosis of paraneoplastic neurological syndrome, and anti-tumor and immunological therapies can help to alleviate symptoms and improve prognosis. However, because of the low incidence of this disease, few reports and no reviews have been published about it so far. This article intends to review the research on CV2/CRMP5 antibody-associated paraneoplastic neurological syndrome and summarize its clinical features to help clinicians comprehensively understand the disease. Additionally, this review discusses the current challenges that this disease poses, and the application prospects of new detection and diagnostic techniques in the field of paraneoplastic neurological syndrome, including CV2/CRMP5-associated paraneoplastic neurological syndrome, in recent years.
Insights
Paraneoplastic neurological syndrome linked to CV2/CRMP5 antibodies can cause diverse neurological symptoms. Early detection of these antibodies is vital for timely treatment and improved patient outcomes.
Area of Science:
- Neurology
- Immunology
- Oncology
Background:
- Paraneoplastic neurological syndromes (PNS) involve nervous system dysfunction due to cancer, without metastasis.
- CV2/collapsin response mediator protein 5 (CRMP5) antibodies are key autoantibodies in PNS, targeting neural antigens.
- These antibodies can lead to varied neurological deficits, including limbic encephalitis, chorea, and ataxia.
Purpose of the Study:
- To review current research on CV2/CRMP5 antibody-associated paraneoplastic neurological syndrome.
- To summarize the clinical manifestations and diagnostic significance of CV2/CRMP5 antibodies.
- To discuss challenges and future diagnostic techniques for this rare condition.
Main Methods:
- Literature review of studies on CV2/CRMP5 antibody and associated neurological syndromes.
- Synthesis of clinical features, diagnostic approaches, and therapeutic strategies.
- Analysis of recent advancements in detection and diagnostic technologies.
Main Results:
- CV2/CRMP5 antibodies are associated with a spectrum of neurological disorders.
- Detection of these antibodies is crucial for diagnosing PNS and guiding treatment.
- The review consolidates information on clinical presentation and management.
Conclusions:
- CV2/CRMP5 antibody detection is essential for diagnosing paraneoplastic neurological syndrome.
- Understanding the clinical features aids in early diagnosis and management.
- Emerging diagnostic tools offer promise for improved detection and patient outcomes.
More Related Videos
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Related Concept Videos
01:15Parkinson's Disease: Overview
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:37Neural Regulation